Skip to main content

Advertisement

SpringerLink
Log in

New Treatments in Rheumatology: Biosimilars

  • Rheumatoid Arthritis (Y Yazici, Section Editor)
  • Published:
Current Treatment Options in Rheumatology Aims and scope Submit manuscript

Abstract

Purpose of review

Biosimilar versions of biologic agents have become increasingly available over the past decade. The framework for regulatory approval has been well established in the USA and Europe, and many biosimilars for use in oncology, rheumatology, dermatology, and inflammatory bowel disease treatment have been approved. Although the utilization of biosimilars has led to substantial cost savings in European countries, this has not occurred in the USA.

Recent findings

In this review, we explore several reasons for the limited uptake of biosimilars in the USA. Discounts and rebates to pharmacy benefits managers and patent litigation are major impediments. Furthermore, physicians and patients in the USA continue to express concerns that biosimilars do not have comparable safety and efficacy, despite abundant scientific evidence to the contrary. The Kaiser and Veterans Administration systems have successfully countered these obstacles and achieved dramatic cost savings as a result. The Kaiser experience illustrates the importance of including prescribing physicians as well as patients as stakeholders in the decision to implement use of biosimilars.

Summary

However, major changes in the operation of the US health system must also occur for the full potential for cost savings to be realized with use of biosimilars as substitutes for our revolutionary but extremely expensive, biologic medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Implementation of the Biologics Price Competition and Innovation Act of 2009 https://www.fda.gov/drugs/guidance-compliance-regulatory-information/implementation-biologics-price-competition-and-innovation-act-2009. Accessed May 13, 2020.

  2. McCormick N, Wallace ZS, Sacks CA, Hsu J, Choi HK. Decomposition analysis of spending and price trends for biologic antirheumatic drugs in Medicare and Medicaid. Arthritis Rheum. 2020;72:234–41. https://doi.org/10.1002/art.41138. A recent discussion of some of the issues which affect pricing.

  3. Schumack GT, Li EC, Wiest MD, Suda KJ, Stubbings J, Matusiak LM, et al. National trends in prescription drug expenditures and projections for 2017. Am J Health Syst Pharm. 2017;74:115–73. https://doi.org/10.2146/ajhp.170164.

    Article  Google Scholar 

  4. Considerations in demonstrating interchangeability with a reference product: guidance for industry. https://www.fda.gov/media/124907/download. Accessed May 13, 2020.

  5. 45 states have passed biosimilar substitution laws. http://www.gabionline.net/Policies-Legislation/45-US-states-have-passed-biosimilar-substitution-laws. Accessed May 7, 2020.

  6. New guide on biosimilar medications for health care professionals. https://www.ema.europa.eu/en/documents/press-release/new-guide-biosimilar-medications-healthcare-professionals-iincreasing-understandng-biosimilar_en.pdf. Accessed May 12, 2020.

  7. Nonproprietary naming of biologic products; guidance for industry. https://www.fda.gov/media/93218/download. Accessed May 13, 2020.

  8. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations. https://www.fda.gov/media/125484/download. Accessed May 13, 2020.

  9. Strand V, Kaine J, Isaacs J. Biosimilars. In: Scott DL, Galloway J, Cope A, Pratt A, Strand V, editors. Oxford Textbook of Rheumatoid Arthritis: Oxford; 2020. A comprehensive review of biosimilar development.

  10. Park W, Hrycaj P, Jeka S, Park W, Kovalenko V, Lysenko G, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–12. https://doi.org/10.1136/annrheumdis-2012-203091. A randomized, double blind study switching to biosimilar infliximab for ankylosing spondylitis.

  11. Assay development and validation testing of the therapeutic protein products: guidance for industry. https://www.fda.gov/media/77796/download. May 11, 2020.

  12. Strand V, Goncalves J, Hickling TP, Jones HE, Marshal L, Isaacs J. Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents. BioDrugs. 2020;34:27–37. https://doi.org/10.1007/s40259-019-00394.

    Article  CAS  PubMed  Google Scholar 

  13. Biosimilar uptake in Europe: big challenges, bigger rewards. https://pharmaboardroom.com/articles/biosimilar-uptake-in-europe-big-challenges-bigger-rewards/ Accessed May 11, 2020.

  14. How the US compares to Europe on biosimilar approvals and products in the pipeline. https://www.bisimilarsip.com/2018/05/02/how-the-us-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline/. Accessed May 11, 2020.

  15. Biosimilar cost savings in the United States. https://www.rand.org/pubs/perspectives/PE264.html. Accessed May 13, 2020.

  16. Roy A. Biologic medicines: the biggest driver of rising drug prices. Forbes. 2019. https://www.forbes.com/sites/theapothecary/2019/03/08/biologic-medicines-the-biggest-driver-of-rising-drug-prices/#6e36b5d218b0. Accessed May 11, 2020.

  17. Socal M, Ballreich J, Chyr L, Anderson G. A report for ERIC–The ERISA Industry Committee Department of Health Policy and Management Johns Hopkins Bloomberg School of Public Health Baltimore, MD; 2020.

  18. Biosimilars action plan: balancing innovation and competition. 2018. https://www.FDA.gove/media/114574/download. Accessed May 11, 2020.

  19. Kim SC, Sarpatwari JD, Landon JE, et al. Utilization and treatment costs of tumor necrosis factor inhibitors after the introduction of biosimilar infliximab in the United States. Arthritis Rheum. 2020;72:1–3. https://doi.org/10.1002/art.41202.

    Article  CAS  Google Scholar 

  20. Yazdany J, Dudley RA, Lin GA, Chen R, Tseng CW. Out-of-pocket costs for infliximab and its biosimilar for rheumatoid arthritis under Medicare part D. JAMA. 2018;320:931–3. https://doi.org/10.1001/jama.2018.7316.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Baker JF, Leonard CE, Lo Re IIIV, Weissman MH, Kay J. Brief report: biosimilar uptake in the academic and veterans health administration settings: influence of institutional incentives. https://doi.org/10.1002/ART.41277. An analysis of how the VA has more incentive than an academic medical center to reduce cost by using biosimilars.

  22. Health Care Advisory: Updates on Biosimilar Reimbursement Pathways in the Face of a Changing Market. https://www.alston.com/en/insights/publications/2018/01/updates-on-biosimilar-reimbursement-pathways. Accessed May 13, 2020.

  23. CMS Payment Policy Plays Role in Biosimilar Uptake. 2020. https://www.centerforbiosimilars.com/conferences/specialty-therapies-and-biosimilars-conference/cms-payment-policy-plays-role-in-biosimilar-uptake. Accessed May 13, 2020.

  24. Yazdany J. Failure to launch: biosimilar sales continue to fall flat in the United States. Arthritis Rheum. 2020;1:1–4. https://doi.org/10.1002/ART.41203 Provides a good explanation of the “rebate trap”.

    Article  Google Scholar 

  25. Pfizer files suit against J&J over Remicade contracts https://www.reuters.com/article/us-pfizer-trial-johnson-john Motion to dismiss Inflectra case denied, but J&J insists “Pfizer’s lawsuit is without merit”. https://www.biopharma-reporter.com/Article/2018/08/14/Motion-to-dismiss-Inflectra-case-denied-but-J-J-insists-Pfizer-s-lawsuit-is-without-merit?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright. Accessed May 13, 2020.

  26. Motion to dismiss Inflectra case denied, but J&J insists “Pfizer’s lawsuit is without merit”. https://www.biopharma-reporter.com/Article/2018/08/14/Motion-to-dismiss-Inflectra-case-denied-but-J-J-insists-Pfizer-s-lawsuit-is-without-merit?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright. Accessed May 13, 2020.

  27. Pending antitrust actions could change biosimilar dynamics. https://www.centerforbiosimilars.com/contributor/ron-lanton-III-esq/20 20/02/pending-antitrust-actions-could-change-biosimilar-dynamics. Accessed May 11, 2020.

  28. Maniadakis N, Holtorf AP, Otavio Correa J, Gialama F, Wijaya K. Shaping pharmaceutical tenders for effectiveness and sustainability in countries with expanding healthcare coverage. Appl Health Econ Health Policy. 2018;16:591–607.

    Article  Google Scholar 

  29. Biosimilar coverage by the VA-what you need to know. https://www.biosimilardevelopment.com/doc/biosimilar-coverage-by-the-va-what-you-need-to-know-0001. Accessed May 11, 2020.

  30. Merck seeing gains for Renflexis at VA. https://www.centerforbiosimilars.com/news/merck-seeing-gains-forrenflexis-at-va. Accessed May 15, 2020.

  31. Venker B, Stephenson KB, Gellad WF. Assessment of spending in Medicare Part D if medication prices from the Department of Veterans Affairs were used. JAMA Intern Med. 2019;179:431–3. https://doi.org/10.1001/jamainternmed-2018.5874.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Promotional labeling and advertising consideration for prescription biological reference ad biosimilar products- questions and answers draft guidance for industry. https://www.fda.gov/media/134862/download. Accessed May 11, 2020.

  33. Another biosimilar receives FDA approval and is confronted with litigation. https://biosimilarsip.com/2019/5/28/another-biosimilar-receives-FDA-approval-and-is-confronted-with-litigation. Accessed May 11, 2020.

  34. In long-awaited decision in etanercept litigation, court sides with Amgen over Sandoz. https://www.centerforbiosimilars.com/news/in-long-awaited-decision-in-etanercept-litigation-court-sides-with-amgen-over-sandoz. Accessed May 11, 2013 33.

  35. Price WN, Rai AK. How logically impossible patents block biosimilars. Nat Biotechnol. 2019;37:862–9. https://doi.org/10.1038/s41587-019-0196-x. A description of how originator companies use patents to delay the marketing of biosimilars.

  36. Hakim A, Ross JS. Obstacles to adoption of biosimilars for chronic diseases. JAMA. 2017:2163–4. https://doi.org/10.1001/jama.2017.5202. A good review of the biosimilar development process and obstacles to marketing.

  37. Teva settles with Roche to launch the first Rituxan biosimilar. https://bioprocessintl.com/bioprocess-insider/global-markets/teva-settle-with-roche-to-launch-first-rituxan-biosimilar-in-us/ Accessed May 11, 2020.

  38. Shim SC, Bozić-Majstorović L, Kasay AB, et al. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized phase 3 trial. Rheumatology. 2019;58:2193–202. https://doi.org/10.1093/rheumatology/kez152.

    Article  CAS  PubMed  Google Scholar 

  39. FDA approves Pfizer’s biosimilar Ruxience rituximab-pvvr for certain cancers and autoimmune conditions. https://markets.businessinsider.com/news/stocks/fda-approves-pfizer-s-biosimilar-ruxience-rituximab-pvvr-for-certain-cancers-and-autoimmune-conditions-1028377494. Accessed May 13, 2020.

  40. Pending antitrust actions could change biosimilar dynamics. https://www.centerforbiosimilars.com/contributor/ron-lanton-III-esq/2020/02/pending-antitrust-actions-could-change-biosimilar-dynamics. Accessed May 11, 2020.

  41. Biosimilar Action Plan: Balancing Innovation and Competition. https://www.FDA.gove/media/114574/download. Accessed May 13, 2020.

  42. The Biologic Transparency Act. https://www.bigmoleculewatch.com/2019/03/21/the-biologic-patent-transparency-act-proposed-revisions-to-purple-book/. Accessed May 11, 2020.

  43. Promotional labeling and advertising consideration for prescription biological reference ad biosimilar products- questions and answers draft guidance for industry. https://www.fda.gov/media/134862/download. Accessed May 11, 2020.

  44. FDA, FTC pledge close cooperation to create biosimilar competition. https://www.centerforbiosimilars.com/news/fda-ftc-pledge-close-cooperation-to-create-biosimilar-competition. Accessed May 11, 2020.

  45. Teeple A, Ellis LA, Huff L, Reynolds C, Ginsburg S, Howard L, et al. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States. Curr Med Res Opin. 2019;35:611–7.

    Article  CAS  Google Scholar 

  46. Critics assail non-medical switching policy in Canadian provinces. https://www.centerforbiosimilars.com/news/critics-assail-nonmedical-switching-policy-in-canadian-provinces. Accessed May 11, 2020.

  47. Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomized, double-blind, non- inferiority trial. Lancet. 2017;389:2304–16. The NOR-SWITCH study is a large Norwegian study in which patients on originator infliximab were switched to a biosimilar.

  48. Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78:192–200. The DANBIO registry examines switching in over 2000 patients in Denmark.

  49. Cantini F, Benucci M. Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching. Ann Rheum Dis. 2018;79. https://doi.org/10.1136/annrheumdis-2018-214757. Another analysis of the DANBIO registry.

  50. Rezk M, Pieper B. Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect. Rheumatol Ther. 2017;4:209–18. https://doi.org/10.1007/s40744-017-0085-z. A good explanation of the “nocebo effect”.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Fleischmann R, Jairath V, Mysler E, Nicholls D, Declerck P. Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology? Rheumatol Ther. 2020;7:35–64. https://doi.org/10.1007/s40744-019-00190-7 [published online ahead of print, January 16, 2020].

  52. Moots R, Azevedo A, Coindreau JL, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep. 2017;19:37. https://doi.org/10.1007/s11926-017-0658-4.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Tweehuysen L, Huiskes VJB, Van den Bemt BJF, et al. Open-abel, non-mandatory transitioning from originator etanercept to biosimilar SB4 six-month results from a controlled cohort study. Arthritis Rheum. 2018;70:1408–18. https://doi.org/10.1002/art.40516.

    Article  CAS  Google Scholar 

  54. How did Kaiser-Permanente reach 95% utilization of biosimilar Herceptin and Avastin so quickly? https://biosimilarsrr.com/2019/11/07/. Accessed May 11, 2020. A good explanation of the process by which Kaiser successfully introduced biosimilars.

  55. Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomized, double-blind, phase 3 non- inferiority study. Lancet. 2019;393:1699–707.

    Article  CAS  Google Scholar 

  56. Employers are in good position to promote biosimilars. https://www.centerforbiosimilars.com/news/employers-are-in-good-position-to-promote-biosimilars. Accessed May 11, 2020.

Download references

Author information

Authors and Affiliations

  1. West County Rheumatology, St. Louis, MO, USA

    Richard Brasington MD, MACR, FACP

  2. Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 94304, USA

    Vibeke Strand MD, MACR, FACP

Authors
  1. Richard Brasington MD, MACR, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vibeke Strand MD, MACR, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vibeke Strand MD, MACR, FACP.

Ethics declarations

Human and animal rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Rheumatoid Arthritis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brasington, R., Strand, V. New Treatments in Rheumatology: Biosimilars. Curr Treat Options in Rheum 6, 325–336 (2020). https://doi.org/10.1007/s40674-020-00159-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40674-020-00159-6

Keywords

Search

Navigation